0001104659-20-137967.txt : 20201221 0001104659-20-137967.hdr.sgml : 20201221 20201221133257 ACCESSION NUMBER: 0001104659-20-137967 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201217 FILED AS OF DATE: 20201221 DATE AS OF CHANGE: 20201221 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GRAYZEL DAVID S. CENTRAL INDEX KEY: 0001732786 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38459 FILM NUMBER: 201403435 MAIL ADDRESS: STREET 1: C/O SURFACE ONCOLOGY STREET 2: 50 HAMPSHIRE ST., 8TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Surface Oncology, Inc. CENTRAL INDEX KEY: 0001718108 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 HAMPSHIRE STREET, 8TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-714-4096 MAIL ADDRESS: STREET 1: 50 HAMPSHIRE STREET, 8TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 a4.xml 4 X0306 4 2020-12-17 0 0001718108 Surface Oncology, Inc. SURF 0001732786 GRAYZEL DAVID S. C/O SURFACE ONCOLOGY, INC. 50 HAMPSHIRE STREET CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2020-12-17 4 S 0 1700000 18.10 D 2945453 I See Footnote # Represents shares sold by Atlas Venture Fund IX, L.P. ("Atlas IX"). Atlas Venture Associates IX, L.P. ("AVA IX LP") is the general partner of Atlas IX. Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. The Reporting Persons owns an interest in AVA IX LP and disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Mr. Grayzel is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. The high, low and average for the shares sold were all $8.10. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) of this Form 4. These shares are held directly by Atlas IX. The sole general partner of Atlas IX is AVA IX LP. AVA IX LLC is the sole general partner of AVA IX LP. The Reporting Persons owns an interest in AVA IX LP and disclaims Section 16 beneficial ownership of the securities held by Atlas IX, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed to an admission that Mr. Grayzel is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. By: /s/ Frank Castellucci -Attorney in Fact 2020-12-21